AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01799798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab will be given subcutaneously in a dosage of 1mg/kg body weight every 12 weeks. 4 interventions are planned until trial week 36. There is no control group planned.
Study NCT02939729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking Programme
Description: Walking programme measured by daily step count on pedometer provided to participant. Participants will be advised to increase daily step count from their baseline measure - realistic incremental rise according to individual ability and symptoms. Daily step count will be recorded in a participant study diary.
Study NCT02939729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Incentive Spirometer
Description: An incentive spirometer is a device used to measure lung tidal volumes. Participants will be asked to use the incentive spirometer to measure their tidal volume daily. Participants will record daily tidal volume measurement in the participant diary. A physiotherapist will teach participants how to use the incentive spirometer and provide an instruction sheet.
Study NCT02939729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep Breathing Exercises
Description: Participants will be taught deep breathing exercises - these are the same deep breathing exercises shown to all patients after cardiac surgery as part of chest physiotherapy treatment. Participants will be asked to carry out deep breathing exercises at home during the prehabilitation phase. An instruction sheet for the deep breathing exercises will be provided to participants.
Study NCT01459003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: beauty care
Description: beauty care performed before each chemo cycle
Study NCT03931876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Single ascending dose administration
Study NCT03931876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AV-006
Description: Single ascending dose administration
Study NCT00721604 — intervention group
Intervention type: DRUG
Intervention: fluid administration
Description: two consecutive infusions of 6% hydroxyethyl starch at the dosage 7 ml/kg over 30 minutes (total 14 ml/kg in 60 minutes)
Study NCT02946125 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MDD-administered EYN-1601
Description: Phenylephrine hydrochloride ophthalmic solution 10% formulated for microdose spray delivery
Study NCT02946125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine 2.5% Eyedrop
Description: Phenylephrine hydrochloride ophthalmic solution 2.5% eyedrop
Study NCT02946125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine 10% Eyedrop
Description: Phenylephrine hydrochloride ophthalmic solution 10% eyedrop
Study NCT02696070 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Provant Therapy System
Study NCT03700242 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HDCV
Description: Pharmaceutical form:Solution for injection Route of administration: Intramuscular
Study NCT03700242 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HDCV
Description: Pharmaceutical form:Solution for injection Route of administration: Intramuscular
Study NCT03700242 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HDCV
Description: Pharmaceutical form:Solution for injection Route of administration: Intradermal
Study NCT03700242 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVRV
Description: Pharmaceutical form:Solution for injection Route of administration: Intramuscular
Study NCT03700242 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVRV
Description: Pharmaceutical form:Solution for injection Route of administration: Intradermal
Study NCT02161913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Family Group Treatment
Study NCT02161913 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SCI Education Control Group
Study NCT04807621 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet transfusion
Description: Platelets (10 ml/kg body weight) is transfused.
Study NCT04807621 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate
Description: Fibrinogen concentrate (300 mg/kg body weight) is administered.
Study NCT01465477 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated split virion Influenza vaccine
Description: WHO recommended 2011 Influenza vaccine
Study NCT01465477 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WHO recommended 2011 Influenza vacccine
Description: WHO recommended 2011 Influenza vacccine
Study NCT04761731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADVAGRAF®
Description: Administration method The total daily dose of tacrolimus will be converted to 1:1 (mg:mg) and the total daily dose of ADVAGRAF® will be administered only once daily in the morning, starting from Day 1 (at least one hour before breakfast or 2 to 3 hours after breakfast).~* Dose adjustment after conversion On Day 1, the total dose will be converted to 1:1. It is recommended to check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 5\~8ng/ml for 0 to 3 months and then at 5ng/ml or below for 3 to 6 months of study treatment.~* Duration of treatment The investigational product will be administered for 24 weeks.
Study NCT03556566 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tableted vaccine (V3-OVA) containing ovarian cancer antigens
Description: One pill of V3-OVA per day for three months
Study NCT03291548 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quinoa biscuit
Description: 2x15g biscuits per day for 28 consecutive days (4 weeks).
Study NCT03291548 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control biscuit
Description: 2x15g biscuits per day for 28 consecutive days (4 weeks).
Study NCT01444443 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop control
Description: Blood glucose controlled by algorithm
Study NCT01444443 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Open-loop control
Description: Blood glucose controlled by patient
Study NCT02339233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standing and Stepping with spinal cord Epidural Stimulation
Description: Standing and Stepping with support from trainers as needed, overground or in a harness with body weight support on a treadmill. Epidural stimulation with specific configurations will be administered to generate standing and stepping.
Study NCT03508622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth group sessions
Description: Telehealth sessions will utilize an online meeting platform and will be conducted by RDs, PTs, psychologists, and MDs, to deliver weight management information/counseling, to group of 5-6 14-18 yos with obesity.
Study NCT03508622 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Empower clinic
Description: Empower visits for the retrospective control group were multi-disciplinary in nature, occurred at CHLA outpatient clinic, and were intended to be monthly (though actual adherence to recommended attendance was variable). Teen and minimum of one family member were asked to attend monthly visits, as per our standard clinical care.
Study NCT02854579 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: neural progenitor cell
Description: Neural progenitor cells are derived from the same aborted human fetal forebrain.
Study NCT02854579 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Paracrine factors
Description: The factors obtained from cultured human mesenchymal stem cells were concentrated 50 times
Study NCT02854579 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: progenitor cell and paracrine factors
Description: Neural progenitor cells will be received after paracrine factors therapy
Study NCT01379664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: Isoflurane is administered to patient during surgery as it would normally be administered by the attending anesthesiologist
Study NCT01379664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane is administered to patient during surgery as it would normally be administered by the attending anesthesiologist
Study NCT01062256 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo tablet administered orally as a single dose
Study NCT01062256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guaifenesin
Description: One 400 mg immediate release tablet administered orally as a single dose
Study NCT01062256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buckwheat Honey
Description: 10 mL administered orally as a single dose
Study NCT03948347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: The treatment arm will receive the starting dose of liraglutide of 0.6 mg/d subcutaneously once daily, and the dose will be increased to 1.8 mg/d in two weeks, and then continue to administrate this dose for 90 days.
Study NCT04692610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stoma prehabilitation
Description: A stoma pouch was attached to the marked stoma site on the patient's abdominal surface after stoma education (only in group C). EST nurse filled 250 ml water into the pouch. Patients lived with these pouches until surgery. They experienced walking, sitting, sleeping, changing clothes with a pouch. They learned how to empty it. When a leak occurred, the pouch was changed by the nurse
Study NCT04692610 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: preoperative stoma education
Description: A consultation period for stoma education by an EST nurse was approximately 45 minutes. Patients were shown pictures of a stoma. The stoma-care equipments and a pouch were also shown to the patients and they were informed about these equipments. They were also provided information about daily living with a stoma.
Study NCT04692610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: preoperative stoma education
Description: A consultation period for stoma education by an EST nurse was approximately 45 minutes. Patients were shown pictures of a stoma. The stoma-care equipments and a pouch were also shown to the patients and they were informed about these equipments. They were also provided information about daily living with a stoma.
Study NCT04692610 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: postoperative stoma education
Description: A consultation period for stoma education by an EST nurse was approximately 45 minutes. Patients were shown pictures of a stoma. The stoma-care equipments and a pouch were also shown to the patients and they were informed about these equipments. They were also provided information about daily living with a stoma.
Study NCT04692610 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: postoperative stoma education
Description: A consultation period for stoma education by an EST nurse was approximately 45 minutes. Patients were shown pictures of a stoma. The stoma-care equipments and a pouch were also shown to the patients and they were informed about these equipments. They were also provided information about daily living with a stoma.
Study NCT04692610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: postoperative stoma education
Description: A consultation period for stoma education by an EST nurse was approximately 45 minutes. Patients were shown pictures of a stoma. The stoma-care equipments and a pouch were also shown to the patients and they were informed about these equipments. They were also provided information about daily living with a stoma.
Study NCT04692610 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Postoperative stoma care
Description: Usual stoma care given by enterostomal therapy nurse after a surgery with fecal diversion
Study NCT04692610 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative stoma care
Description: Usual stoma care given by enterostomal therapy nurse after a surgery with fecal diversion
Study NCT04692610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postoperative stoma care
Description: Usual stoma care given by enterostomal therapy nurse after a surgery with fecal diversion
Study NCT02315690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine (DHAp)
Description: In the fMDA arm, all individuals in the target area will receive dihydroartemisinin-piperaquine (DHAp) once daily for 3 days with the first dose taken no later than 5 weeks from the index case presentation (goal within one week).
Study NCT02315690 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: reactive case detection
Description: Individuals in RACD target areas will be tested by RDT and if positive will be taken to the nearest health facility for treatment as per program operating procedures.
Study NCT01451762 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: .9 normal saline
Description: .9 normal saline administered before surgery.
Study NCT01451762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25 mg diphenhydramine IV
Description: 25 mg diphenhydramine IV administered before surgery
Study NCT01451762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 mg diphenhydramine IV
Description: 50 mg diphenhydramine administered IV before surgery
Study NCT02506582 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: jerusalem artichoke and fermented soybeans powder mixture
Description: 40 g jerusalem artichoke and fermented soybean powder mixture
Study NCT02506582 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 40 g powdered rice flour
Study NCT01909557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetyl-L-carnitine
Study NCT01909557 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02430870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-648
Description: TAK-648 solution
Study NCT02430870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-648 placebo-matching solution
Study NCT03299296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 Milligrams
Description: The first group is to be on Rivaroxaban 10 mg with dosage according to the orthopedic approved regimen (10 mg once daily 6-10 hours after the surgery; recommended total duration of therapy: 12 to 14 days; The American College of Chest Physicians (ACCP) recommendation: Minimum of 10 to 14 days; extended duration of up to 35 days suggested.
Study NCT03299296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 40 Milligrams/0.4 Milliliters Prefilled Syringe
Description: The other group will be administered the standard of care (SOC) enoxaparin as follows:~Once-daily dosing: 40 mg once daily, with initial dose within 9 to 15 hours before surgery, and daily for at least 10 days (or up to 35 days postoperatively) or until risk of deep venous thrombosis (DVT) has diminished or the patient is adequately anticoagulated on warfarin. The American College of Chest Physicians recommends initiation ≥12 hours preoperatively or ≥12 hours postoperatively; extended duration of up to 35 days suggested.
Study NCT02242201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PNB Bupivacaine
Description: Infusion
Study NCT02242201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PAI Ropivacaine
Description: Injection
Study NCT02242201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PAI liposomal bupivacaine
Description: Injection
Study NCT02242201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Injection, weight-based dosage of 100 mcg - 300 mcg
Study NCT02242201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Injection, 30 mg
Study NCT01934673 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: Patients will fill out a questionnaire by interview.
Study NCT01895296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: somatostatin analogue pasireotide
Study NCT01895296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo s.c.
Study NCT05084001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silver diamine fluoride
Description: topical application of the agent on tooth surface
Study NCT05084001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium fluoride varnish
Description: topical application of the agent on tooth surface
Study NCT05084001 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: tonic water
Description: topical application of tonic water on tooth surface
Study NCT02285738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 81mg/day for 4 weeks
Study NCT02285738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 81mg/day for 4 weeks
Study NCT02285738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Daily dose of Simvastatin for 4 weeks
Study NCT02285738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Daily dose of Simvastatin for 4 weeks
Study NCT02285738 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: participants will be observed for thrombotic evens for 4 weeks
Study NCT02285738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: participants will be observed for thrombotic evens for 4 weeks
Study NCT04625114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camostat
Description: Standard of care (SOC) + Camostat mesilate (Foipan) 100mg 3 tablets 3 times a day for 5 consecutive days (D1->D5);
Study NCT04625114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SOC + placebo 500 mg 3 tablets 3 times a day for five consecutive days (D1->D5).
Study NCT04625114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camostat
Description: Standard of care (SOC) + Camostat mesilate (Foipan) 100mg 3 tablets 3 times a day for 5 consecutive days (D6->D10);
Study NCT04625114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SOC + placebo 500 mg 3 tablets 3 times a day for five consecutive days (D6->D10).
Study NCT04494867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Core Warming
Description: Esophageal heat transfer device will be set to 42°C temperature after initial placement, and maintained at 42°C for the duration of treatment.
Study NCT04494867 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard temperature management and treatment
Study NCT02143765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitiglinide
Description: three times a day, orally, for 12 weeks
Study NCT02143765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: three times a day, orally, for 12 weeks
Study NCT03328780 — intervention group
Intervention type: DEVICE
Intervention: Hemocue and Rad-67 measurement
Description: Measurement of the hemoglobin level
Study NCT02589171 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neo Close Abdominal Closure
Description: Neo Close Abdominal Closure
Study NCT02589171 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carter Thomason Device
Description: Carter Thomason Device
Study NCT04439396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: nonsteroidal anti-inflammatory drug
Study NCT04439396 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: saline fluid injection
Study NCT04345965 — intervention group
Intervention type: PROCEDURE
Intervention: Endovascular procedure
Description: Endovascular therapies for erectile dysfunction
Study NCT01621165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Addition of prazosin to usual care (add-on study)
Description: Prazosin and placebo will be gradually titrated over 10 days to a final dose of 10 mg/day, given in divided doses (three times a day). During this time subjects will be monitored for adverse effects to prazosin and manic symptoms will be monitored. Vital signs will be monitored three times a day throughout the study. If a subject receiving prazosin or placebo develops distressing adverse effects, the dose will be decreased to the next lower dose.If there is a greater than 15 mg mercury postural fall in systolic bBP, dosing will be held at the previous day's dose.Subjects who do not tolerate prazosin or placebo will be discharged from the study.